IceCure Medical’s ProSense® Shows Promising Results in Endometriosis Treatment

An announcement from Icecure Medical ( (ICCM) ) is now available.

On September 4, 2025, IceCure Medical announced promising results from an independent study on their ProSense® cryoablation technology for treating abdominal wall endometriosis (AWE). Conducted at Nîmes University Hospital, the study showed significant pain reduction and high procedural efficacy, with median pain scores dropping from 8 to 0. The study supports ProSense® as a safe, effective, and minimally invasive treatment option, enhancing its commercial potential and industry positioning.

The most recent analyst rating on (ICCM) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.

Spark’s Take on ICCM Stock

According to Spark, TipRanks’ AI Analyst, ICCM is a Neutral.

Icecure Medical’s overall stock score reflects significant financial challenges, including declining revenues and substantial losses. While there is optimism regarding regulatory progress and clinical achievements, these are overshadowed by financial instability and valuation concerns. Technical analysis indicates potential short-term momentum, but overbought conditions could lead to a pullback.

To see Spark’s full report on ICCM stock, click here.

More about Icecure Medical

IceCure Medical, listed on Nasdaq as ICCM, develops and markets advanced cryoablation therapy systems using liquid nitrogen to destroy tumors by freezing. The company’s primary focus areas include breast, kidney, bone, and lung cancer. Its flagship product, the ProSense® system, is marketed globally and offers a minimally invasive alternative to traditional surgical tumor removal.

Average Trading Volume: 1,584,069

Technical Sentiment Signal: Hold

Current Market Cap: $74.19M

See more data about ICCM stock on TipRanks’ Stock Analysis page.